Current Open Trials
CC# 21708 (Fong, Lawrence) - A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Learn more
CC# 22701 (Keenan, Bridget) - A PHASE 1/2 STUDY OF RTX-224 FOR THE TREATMENT OF PATIENTS WITH ADVANCED SOLID TUMORS
Learn more
CC# 21704 (Keenan, Bridget) - A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects With Advanced Malignancies
Learn more
CC# 22705 (Keenan, Bridget) - A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Learn more
CC# 217013 (Fong, Lawrence) - A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION TRIAL OF THE SAFETY OF AND ANTIGEN-SPECIFIC IMMUNE RESPONSES ELICITED BY VB.10 NEO IN COMBINATION WITH ATEZOLIZUMAB IN SUBJECTS WITH LOCALLY ADVANCED AND METASTATIC TUMORS
Learn more
CC# 22703 (Oh, David) - A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Learn more
CC# 20707 (Oh, David) - A Phase 1 Dose Escalation and Expanded Cohort Study of P-PSMA-101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Learn more
CC# 197010 (Oh, David) - A Phase 1/2 Single Arm Open-Label Clinical Trial of Gavocabtagene Autoleucel (Gavo-cel) in Patients With Advanced Mesothelin-Expressing Cancer
Learn more
CC# 197017 (Oh, David) - A Phase II Study of Perioperative Pembrolizumab-Based Therapy in Patients with Locally Advanced or Metastatic Renal Cell Carcinoma Prior to Cytoreductive Nephrectomy or Metastasectomy
Learn more
CC# 217012 (Fong, Lawrence) - A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AMG 340, a Bispecific Antibody Targeting PSMA in Subjects with Metastatic Castrate-resistant Prostate Carcinoma (mCRPC)
Learn more
CC# 21705 (Algazi, Alain) -Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies
Learn more